Helsinn v. Teva

The Supreme Court Weighs in on the On- Sale Bar and the State of Secret Prior Art

April 29, 2019 11:00am

Colman Ragan
VP & General Counsel, North America IP Litigation
Teva Pharmaceuticals

Joseph O’Malley
Paul Hastings LLP (New York, NY)

Stephen S. Rabinowitz
Dechert LLP (New York, NY)

Ben Katzenellenbogen
Knobbe Martens (Irvine, CA)

Jovial Wong
Winston & Strawn LLP (Washington, DC)

On January 22, 2019, the Court released its opinion in Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA Inc., (Supreme Court No. No. 17-1229). This panel will explore the current state of on-sale bar jurisprudence as they engage in a lively point-counterpoint discussion in view of the monumental decision.
  • Reviewing the Supreme Court’s opinion and it its nuances relative to how a secret sale constitutes prior art
    • Understanding the Court’s interpretation of how the AIA altered the on-sale bar
  • Assessing whether prior art patents and printed publications will continue to play a central role in patent invalidations in a post-Helsinn world in light of the Court’s decision
  • Deciding whether an inventor’s sale of an invention to a third party that is required to keep the invention confidential qualifies as prior art for the purposes of determining patentability
  • Analyzing whether the phrase “available to the public” implies a distinct restraint on issuance or if it adjusts the two prior limitations that appear before it